Glucotrack Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Glucotrack Inc in the second quarter 2026?
Glucotrack Inc achieved a return on average equity (ROE) of 1114.03 % in its second quarter 2026, this is above GCTK's average return on equity of 356.12%.
Glucotrack Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $1 million

While the company's net income was fading, Glucotrack Inc was able to improve its ROE compared to the first quarter 2026.

Within the Medical Equipment & Supplies industry Glucotrack Inc achieved the highest return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 11, from total ROE ranking in the first quarter 2026 at 12.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	-	-36.57 %	-64.06 %	-18.01 %	5.95 %
Net Income (TTM) in Millions	8	17	19	26	27
Return On Equity (TTM)	1114.03 %	581.98 %	393.33 %	2659.19 %	-
GCTK's Total Ranking	# 11	# 12	# 13	# 4	# 0
Equity (TTM) in Millions	-2	-1	3	3	7
Seq. Equity Change	-	-	2.8 %	-60.01 %	-5.21 %
Seq. Net Income Change	-	19.46 %	-13.02 %	-12.3 %	-30.4 %

Back to GCTK Management Effectiveness >> GCTK's 5 Years Annual ROE >> Compare GCTK ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 0
Sector	# 2
Overall	# 11

Return On Equity Statistics
High	Average	Low
2659.19 %	356.12 %	-242.7 %
(Sep 30 2025)		(Mar 31 2020)

GCTK Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	3	-13	3	1	5
Y / Y Equity Change	-	-	159.92 %	-76.14 %	-42.61 %
Net Income in Millions	19	23	7	4	4
Y / Y Net Income Change	-14.2 %	218.4 %	60.02 %	9.05 %	50.85 %
Return On Equity	685.57 %	-	221.99 %	360.57 %	78.89 %

Back to GCTK Management Effectiveness >> GCTK's 5 Years Annual ROE >> Compare GCTK ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 685.57 % compared to the prior year.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GCTK's' Return on Equity at Yahoo Finance
GCTK's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GCTK's Competitors
Subscribers only: Roe for Glucotrack Inc 's Suppliers
Subscribers only: Return On Equity for GCTK's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Glucotrack Inc	1,114.03 %
Elutia Inc	940.81 %
Meiragtx Holdings Plc	283.67 %
Silexion Therapeutics Corp	276.59 %

Date modified: 2026-08-31T23:26:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.